EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
By: Feng Li, Yongmei Liu, Huijiao Chen, Dianying Liao, Yali Shen, Feng Xu and Jin Wang

Journal of Experimental & Clinical Cancer Research 2011, 30:27 doi:10.1186/1756-9966-30-27
Published: 7 March 2011

Abstract (Provisional)

Background

To evaluate the expression of EGFR and COX-2 and their correlation with prognosis in NSCLC.

Methods

The paraffin embedded tumor samples of 50 NSCLC patients receiving radical resection were analyzed immunohistochemically for EGFR and COX-2 expression and their prognostic values were explored.

Results

The positive rate of EGFR protein in NSCLC tumor cells was 46% which was significantly higher than its expression in normal lung (p = 0.0234) and para-cancerous tissues(p = 0.020). EGFR expression was significantly higher in nodal positive than in nodal negative patients (p = 0.04). The mean survival time for EGFR positive patients (31 months) was significantly lower than that for patients with EGFR negative expression (48 months) (p=0.008,). In patients receiving post-operation thoracic irradiation, the mean survival time for EGFR positive patients was significantly lower than that for patients without EGFR positive expression (25 vs. 48 months, P=0.004). The positive rate of COX-2 protein expression in NSCLC tumor cells was 90%, which was significantly higher than that in normal lung tissue(p = 0.00) and paracancerous tissue (p=0.00). There was no correlation between COX-2 expression and patient survival, and no correlation between COX-2 and EGFR protein expression (P = 0.555).

Conclusions

COX-2 and EGFR are over-expressed in NSCLC. EGFR is an independent prognostic factor and a predictive factor for radiotherapy response in NSCLC.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements